

HYDROMORPHONE THERAPYCROSS REFERENCE TO RELATED APPLICATIONS

This application is a division of U.S. Application Serial No. 08/935,223 filed on September 22, 1997, which application Serial No. 08/935,223 is a continuation-in-part of U.S. Application Serial No. 08/611,294 filed on March 5, 1996 now U.S. Patent No. 5,702,725 issued December 30, 1997, which application Serial No. 08/935,223 is a continuation of U.S. Application Serial No. 08/271,593 filed July 7, 1994 and now U.S. Patent No. 5,529,787 issued on June 25, 1996.

FIELD OF THE INVENTION

This invention pertains to a novel dosage form comprising hydromorphone for the management of pain. The invention concerns also a novel therapeutic composition comprising hydromorphone indicated for treating pain. The invention relates additionally to a method for the management of pain by administering continuously release-rate controlled doses of hydromorphone over an extended time to produce analgesic therapy.

BACKGROUND OF THE INVENTION

Hydromorphone is an analgesic with its principal therapeutic effect, the relief of pain. The precise mechanism of action of hydromorphone is not medically understood, although it is thought to relate to the existence of hydromorphone receptors in the central nervous system. Generally, the analgesic action of parenterally administered hydromorphone is apparent within fifteen minutes and the onset of action of orally administered hydromorphone is somewhat slower, with analgesia occurring within thirty minutes. In human plasma, the half-life of hydromorphone is about two and one-half hours. Hydromorphone is indicated for the relief of moderate to

0905536.071301

1 severe pain, such as pain due to infection, surgery, cancer, trauma, biliary
2 colic, disease, renal colic, myocardial infarction, and burns. A
3 pharmaceutically-acceptable dosage form for oral administering
4 hydromorphone to provide analgesic therapy beyond its short half-life at a
5 controlled-rate over an extended period of time appears to be lacking in the
6 pharmaceutical and medical arts. The pharmacological and medical
7 properties of hydromorphone are known in Pharmaceutical Sciences,
8 Remington, 17th Ed., pp. 1099-1044, (1985); and in the Pharmacological
9 Basis of Therapeutics, Goodman and Rall, 8th Ed., pp. 485-518, (1990).

10 The present invention unexpectedly provides both a dosage form
11 comprising hydromorphone and a therapeutic composition comprising
12 hydromorphone for the management of pain. That is, the prior art did not
13 appreciate that hydromorphone, which is a complex chemical 4,5- epoxy-3-
14 hydroxy-17-methyl-morphinan-6-one, comprising five rings substituted with
15 different chemical groups, can be made into a continuous release dosage
16 form, or into a therapeutic composition. The prior did not appreciate a dosage
17 form and a therapeutic composition can be made available comprising an
18 osmogel such as a polyalkylene oxide and other ingredients including an
19 osmagent. The prior art did not make obvious hydromorphone formulated
20 with a polyalkylene oxide, as the mechanism which controlled the release of
21 hydromorphone from polyalkylene oxide are complex polymers. For example,
22 the hydromorphone could become immobile and trapped in the polyalkylene
23 oxide, also, the polyalkylene oxide could exhibit unacceptable swelling in the
24 presence of aqueous including biological fluid and thereby change the rate of
25 release of the hydromorphone from the polyalkylene oxide. Further, the
26 osmogel such as polyalkylene oxide, can possess a glass-transition
27 temperature below human body temperature, which leads away from using
28 hydromorphone in such an environment. Additionally, the properties of
29 hydromorphone and polyalkylene oxide, exemplified by the crystallinity of
30 hydromorphone in polyalkylene oxide, the burst or lag effect of

0905526-071301

1 hydromorphone in polyalkylene oxide, the hydromorphone solubility in a
2 polyalkylene oxide hydrogel all attest to the nonobviousness of the present
3 invention.

4 Prior to this invention, hydromorphone was administered in
5 conventional forms, such as a nonrate-controlling dose-dumping tablet or by a
6 dose-dumping capsule, and usually at multiple, repetitive dosing intervals.
7 This prior-art mode of therapy leads to an initial high dose of hydromorphone
8 in the blood, followed by a decreased dose of hydromorphone in the blood.
9 The concentration differences in dosing patterns are related to the presence
10 and absence of administered drug, which is a major disadvantage associated
11 with conventional dosage forms. Conventional dosage forms and their mode
12 of operation, including dose peaks and valleys, are discussed in
13 Pharmaceutical Sciences, Remington, 18th Ed., pp 1676-1686, (1990), Mark
14 Publishing Co.; The Pharmaceutical and Clinical Pharmacokinetics, 3rd Ed.,
15 pp 1-28, (1984), Lea and Febiger, Philadelphia.; and in U.S. Patent Numbers
16 3,598,122 and 3,598,123, both issued to Zaffaroni.

17 The above presentation dictates of the critical need for a dosage form
18 and for a therapeutic composition that overcomes the shortcomings of
19 conventional dosage forms, including tablets, capsules, elixirs and
20 suspensions. These conventional dosage forms and their accompanying
21 peaks and valleys do not provide for dose-regulated drug therapy over an
22 extended period of time. The hydromorphone as delivered by the prior art is
23 often dosed two or more times a day, which does not lend itself to controlled
24 and sustained therapy. This prior-art pattern of drug administration speaks of
25 the need for a dosage form and for a therapeutic composition that can
26 administer hydromorphone in a rate-controlled dose over an extended time to
27 provide constant therapy, and thereby eliminate the peaks, valleys, and
28 multiple uncontrolled dosing of the prior art.

29 In view of the foregoing presentation, it is immediately apparent that a
30 serious need exists for an improvement in the delivery of hydromorphone for

09905526-071301

1 its therapeutic analgesic effect. The need exists to provide a novel
2 therapeutic composition comprising hydromorphone, and the need exists to
3 provide a novel method of administering hydromorphone to a patient in need
4 of hydromorphone therapy. The invention provides an oral, relatively-easy to
5 administer mode and manner of hydromorphone therapy.

OBJECTS OF THE INVENTION

6
7
8 Accordingly, in view of the above presentation it is an immediate object
9 of this invention to provide a dosage form and a therapeutic composition for
10 delivering hydromorphone for pain relief, which dosage form and therapeutic
11 composition overcome the shortcomings known to the prior art.

12 Another object of the present invention is to make available to the
13 medical-pharmaceutical art a dosage form that delivers a member selected
14 from the group consisting of hydromorphone and its pharmaceutically
15 acceptable salts in a sustained-release dosage program over time.

16 Another object of the invention is to provide a novel dosage form for
17 administering hydromorphone to a patient at a controlled rate and in a
18 continuous dose over time.

19 Another object of the invention is to provide a therapeutic composition
20 comprising an orally administrable solid hydromorphone comprising an
21 osmopolymer that can be administered as an oral, solid therapeutic
22 composition or administered from an osmotic dosage form comprising the
23 solid initially dry therapeutic composition.

24 Another object of the invention is to provide a pharmaceutically
25 acceptable composition comprising a member selected from the group
26 consisting of hydromorphone and its pharmaceutically acceptable salts for the
27 relief of moderate to severe pain due to surgery, cancer, trauma, tissue, bone,
28 colic, myocardial infarction, burns and rectal pain in a human patient.

09905526-071301

1 Another object of the invention is to provide a therapeutic composition
2 comprising hydromorphone and an osmotic attractant for delivering a known
3 concentration per unit time for hydromorphone therapy.

4 Another object of the invention is to provide a hydromorphone
5 formulation that delivers, in a controlled-continuous releasing dose,
6 hydromorphone to a patient in need of hydromorphone therapy for
7 maintaining a hydromorphone level in the blood as a function of the
8 hydromorphone releasing formulation.

9 Another object of the invention is to provide both a novel dosage form
10 and a novel dosage composition, which in both form, delivers hydromorphone
11 as an analgesic to relieve pain by altering the psychological response to pain
12 and suppress anxiety and apprehension in a patient.

13 Another object of the invention is to provide a method for administering
14 hydromorphone to a patient for lessening a patient's pain.

15 Another object of the invention is to make available a composition
16 comprising hydromorphone blended with a pharmaceutically acceptable
17 polymer and an osmotically active agent.

18 Another object of the invention is to provide a dosage form comprising
19 an external coat comprising hydromorphone for immediate hydromorphone
20 therapy.

21 Another object of the invention is to provide a dosage form that
22 delivers hydromorphone that reduces and/or eliminates the unwanted
23 influences of a gastrointestinal environment on the delivery of hydromorphone
24 from the dosage form in the gastrointestinal tract of a human.

25 Other objects, features and advantages of the invention will be more
26 apparent to those versed in the dispensing art, and from the accompanying
27 detailed specification, then in conjunction with the accompanying claims.

28
29
30

09905526-071301

BRIEF DESCRIPTION OF THE DRAWING

The drawing figures are not drawn to scale, and are set forth to illustrate various embodiments of the invention. The drawing figures are as follows:

Drawing Figure 1 is a general view of a dosage form provided by this invention, designed and shaped for the oral administration of hydromorphone at a controlled rate over an extended time to a patient in need of hydromorphone therapy;

Drawing Figure 2 is a general view of the dosage form of drawing Figure 1, in opened section, depicting a dosage form of the invention comprising an internally housed, pharmaceutically-acceptable therapeutic hydromorphone composition;

Drawing Figure 3 is an opened view of drawing Figure 1, illustrating a dosage form internally comprising a hydromorphone composition and a separate and contacting displacement composition comprising means for pushing the pharmaceutical hydromorphone composition from the dosage form;

Drawing Figure 4 is a view of a dosage form provided by this invention, which dosage form is illustrated comprising an instant-release external overcoat on the dosage form, which overcoat comprises an instant dose of hydromorphone for the lessening of pain;

Drawing Figure 5 depicts the mean plasma hydromorphone concentration profile for hydromorphone;

Drawing Figure 6 depicts the mean plasma hydromorphone 3-glucuronide concentration following hydromorphone treatment; and

Drawing Figure 7 depicts the mean plasma hydromorphone concentration profile for hydromorphone treatment.

Drawing Figures 8 to 12 depict release rate patterns and clinical data provided by the invention.

09905526-071301

1 In the drawing figures and in the specification, like parts in related
2 figures are identified by like numbers. The terms appearing earlier in the
3 specification and in the description of the drawing figures, as well as
4 embodiments thereof, are further described elsewhere in the disclosure.

5 6 DETAILED DESCRIPTION OF DRAWINGS

7 Turning now to the drawing figures in detail, which drawing figures are
8 examples of a dosage form and a therapeutic composition provided by this
9 invention, and which examples are not to be construed as limiting, one
10 example of a dosage form is seen in drawing Figure 1. In drawing Figure 1, a
11 dosage form 10 is seen comprising a body member 11 that comprises a wall
12 12. Wall 12 is an exterior wall, and it surrounds and defines an internal area,
13 or compartment, not seen in drawing Figure 1. Dosage form 10 comprises at
14 least one exit 13 that connects an exterior environment, such as the
15 gastrointestinal tract of a human, with the interior of dosage form 10.

16 Dosage form 10 of drawing Figure 2 illustrates a dosage form
17 comprising controlled-release delivery kinetics that delivers a member
18 selected from the group consisting of hydromorphone and its
19 pharmaceutically acceptable salts. The phrase "controlled-release" denotes
20 that dosage form 10 controls or governs the delivery of hydromorphone 14,
21 represented by dots, from internal space or compartment 15. The controlled-
22 release also denotes the delivery of hydromorphone is at a known rate per
23 unit time, over an extended time or thirty-minutes up to twenty-four hours.
24 Dosage form 10, as provided by this invention, is useful for establishing
25 therapeutic hydromorphone therapeutic levels in the blood, including plasma,
26 as a analgesic or pain-lessening therapy. Dosage form 10 as seen in Figure
27 2, embraces the shape of a dosage tablet, and it could embrace the shape of
28 a caplet and other oral, buccal, or sublingual dosage forms. The extended-
29 continuous delivery time for the sustain-release dosage form 10, provided by
30 the invention, denotes a sustained-release delivery time greater than

09905526-071304

1 conventional, noncontrolled tablets, and noncontrolled, nonsustained-release
2 capsules that exhibit a dose-dumping of their drug.

3 In drawing Figure 2, dosage form 10 is seen in opened-section with a
4 section of wall 12 removed for illustrating the internal area 15 of dosage form
5 10. In drawing Figure 2, dosage form 10 comprises body 11, wall 12, exit 13
6 and internal area or compartment 15. Wall 12, which surrounds and defines
7 internal compartment 15, comprised totally or in at least a part, a
8 semipermeable composition. The phrase "semipermeable composition:
9 denotes that the semipermeable composition is permeable to the passage of
10 an exterior fluid, such as aqueous and biological fluid, in the environment of
11 use, including the gastrointestinal tract. Wall 12 is impermeable to
12 hydromorphone, represented by dots 14, present in compartment 15. Wall 12
13 is nontoxic, inert, and it maintains its physical and chemical integrity during
14 the dispensing life of hydromorphone. Wall 12 comprises a composition that
15 does not adversely effect an animal, a human, or components of the dosage
16 form. Wall 12, in one embodiment, comprises a member selected from the
17 group consisting of a cellulose ester polymer, a cellulose ether polymer and a
18 cellulose ester-ether polymer. These cellulosic polymers have a degree of
19 substitution (DS) on the anhydroglucose unit, from greater than zero up to
20 three inclusive. By "degree of substitution" is meant that the average number
21 of hydroxyl groups originally present on the anhydroglucose unit comprising
22 the cellulose polymer that are replaced by a substituting group.
23 Representative wall 12 polymers comprise a member selected from the group
24 consisting of cellulose acylate, cellulose diacylate, cellulose triacylate,
25 cellulose acetate, cellulose diacetate, cellulose triacetate, mono-, di- and
26 tricellulose alkenylates, and mono-, di- and tricellulose alkynylates. Exemplary
27 polymers include cellulose acetate having a DS up to 1 and an acetyl content
28 up to 21%; cellulose acetate having a DS of 1 to 2 and an acetyl content of 21
29 to 35%; cellulose acetate having a DS of 2 to 3 and an acetyl content of 35 to
30 44.8%. More specific cellulosic polymers comprise cellulose propionate

09905526.071301

1 having a DS of 1.8 and a propyl content of 39.2 to 45% and a hydroxy content
2 of 2.8 to 5.4; cellulose acetate butyrate having a DS of 1.8, and acetyl content
3 of 13 to 15% and a butyryl content of 34 to 39%; cellulose acetate butyrate
4 having an acetyl content of 2 to 29%, a butyryl content of 17 to 53% and a
5 hydroxyl content of 0.5 to 4.7; cellulose triacylates having a DS of 2.9 to 3,
6 such as cellulose trivalerate, cellulose trilaurate, cellulose tripalmitate,
7 cellulose trisuccinate, and cellulose trioctanoate; celluloses diacylate having a
8 DS of 2.2 to 2.6, such as cellulose disuccinate, cellulose dipalmitate, cellulose
9 dioctanoate, cellulose dipentanoate, co-esters of cellulose, such as cellulose
10 acetate butyrate, and cellulose acetate propionate. The poly(cellulose) used
11 for the present invention comprises a number-average molecular weight of
12 20,000 to 7,500,000.

13 Additional semipermeable polymers for the purpose of this invention
14 comprise acetaldehyde dimethylcellulose acetate, cellulose acetate
15 ethylcarbamate, cellulose acetate methylcarbamate, cellulose diacetate,
16 propylcarbamate, cellulose acetate diethylaminoacetate; semipermeable
17 polyamide; semipermeable polyurethane; semipermeable sulfonated
18 polystyrene; semipermeable cross-linked polymer formed by the
19 coprecipitation of a polyanion and a polycation as disclosed in U.S. Patents
20 Nos. 3,173,876; 3,276,586; 3,541,005; 3,541,006 and 3,546,876;
21 semipermeable polymers as disclosed by Loeb and Sourirajan in U.S. Patent
22 No. 3,133,132; semipermeable crosslinked polystyrenes; semipermeable
23 cross-linked poly(sodium styrene sulfonate); semipermeable crosslinked
24 poly(vinylbenzyltrimethyl ammonium chloride); and semipermeable polymers
25 possessing a fluid permeability of 2.5×10^{-8} to 2.5×10^{-2} (cm²/hr•atm)
26 expressed per atmosphere of hydrostatic or osmotic pressure difference
27 across the semipermeable wall. The polymers are known to the polymer art
28 in U.S. Patents Nos. 3,845,770; 3,916,899 and 4,160,020; and in Handbook
29 of Common Polymers, Scott, J.R. and W.J. Roff, 1971, CRC Press,
30 Cleveland, OH.

09905526-071301

09905526.071301

1 The drug hydromorphone 14, as seen in drawing Figure 2, is
2 comprised of: 4,5-epoxy-3-hydroxy-17-methylmorphinan-6-one, possessing
3 analgesic therapy. Hydromorphone is known in The Merck Index, 11th Ed., p.
4 762 (1990). Representative of hydromorphones 14 for this invention
5 comprise a member selected from the group consisting of hydromorphone
6 and its pharmaceutically acceptable salt. The hydromorphone salts are
7 represented by a member selected from the group consisting of the following:
8 hydromorphone sulfate, hydromorphone hydrochloride, hydromorphone
9 trifluoroacetate, hydromorphone thiosemicarbazone hydrochloride,
10 hydromorphone pentafluoropropionate, hydromorphone p-nitrophenyl-
11 hydrozone, hydromorphone hydrazine, hydromorphone hydrobromide,
12 hydromorphone mucate, hydromorphone methylbromide, hydromorphone
13 oleate, hydromorphone n-oxide, hydromorphone acetate, hydromorphone
14 phosphate dibasic, hydromorphone phosphate monobasic, hydromorphone
15 inorganic salt, hydromorphone organic salt, hydromorphone acetate
16 trihydrate, hydromorphone bis(heptafluorobutyrate), hydromorphone
17 bis(methylcarbamate), hydromorphone (bis-pentafluoropropionate),
18 hydromorphone bis(pyridine-3-carboxylate), hydromorphone
19 bis(trifluoroacetate), hydromorphone bitartrate, hydromorphone
20 chlorohydrate, and hydromorphone sulfate pentahydrate. The dosage form
21 and the therapeutic composition in either manufacture comprises 1 mg to 500
22 mg of hydromorphone 14 or hydromorphone 14 pharmaceutically acceptable
23 salt.

24 The hydromorphone composition provided by the present invention
25 comprises hydromorphone 14 blended with a pharmaceutically acceptable
26 hydrogel polymer 16, represented by dashes. Representative polymer
27 hydrogels comprise a maltodextrin polymer comprising the formula $(C_6H_{12}O_5)_\lambda \cdot$
28 H_2O , wherein λ is 3 to 7,500, and the maltodextrin polymer comprises a 500 to
29 1,250,000 number-average molecular weight; a poly(alkylene oxide)
30 represented by a poly(ethylene oxide) and a poly(propylene oxide) having a

1 50,000 to 750,000 weight-average molecular weight, and more specifically
2 represented by a poly(ethylene oxide) of at least one of 100,000, 200,000,
3 300,000 or 400,000 weight-average molecular weights; an alkali
4 carboxyalkylcellulose, wherein the alkali is sodium or potassium, the alkyl is
5 methyl, ethyl, propyl, or butyl of 10,000 to 175,000 weight-average molecular
6 weight; and a copolymer of ethylene-acrylic acid, including methacrylic and
7 ethacrylic acid of 10,000 to 500,000 number-average molecular weight. The
8 therapeutic composition comprises 20 to 375 mg of a polymer hydrogel. The
9 therapeutic composition can be manufactured into dosage form 10, and or
10 can be used as the therapeutic composition for its therapeutic effect.

11 Dosage form 10 comprises a therapeutically acceptable vinyl polymer
12 represented by vertical dashes 17. The vinyl polymer comprises a 5,000 to
13 350,000 viscosity-average molecular weight, represented by a member
14 selected from the group consisting of poly-n-vinylamide, poly-n-vinyl-
15 acetamide, poly(vinyl pyrrolidone), also known as poly-n-vinylpyrrolidone,
16 poly-n-vinylcaprolactone, poly-n-vinyl-5-methyl-2-pyrrolidone, and
17 poly-n-vinyl-pyrrolidone copolymers with a member selected from the group
18 consisting of vinyl acetate, vinyl alcohol, vinyl chloride, vinyl fluoride, vinyl
19 butyrate, vinyl laurate, and vinyl stearate. The dosage form 10, and the
20 therapeutic composition comprises 0.01 to 25 mg of the binder or vinyl
21 polymer, that serves as a binder. Representative of other binders include:
22 acaia, starch, gelatin, and hydroxypropylalkylcellulose of 9,200 to 250,000
23 molecular weight.

24 The dosage form comprises a lubricant 18 represented by a wavy line.
25 The lubricant is used during manufacture to prevent sticking to die walls or
26 punch faces. Typical lubricants include: magnesium stearate, sodium
27 stearate, stearic acid, calcium stearate, magnesium oleate, oleic acid,
28 potassium oleate, caprylic acid, sodium stearyl fumarate, and magnesium
29 palmitate. The amount of lubricant present in the therapeutic composition is
30 0.01 mg to 10 mg.

09905526-071301

1 Drawing Figure 3 depicts dosage form 10 in opened section, illustrating
2 internal compartment 15. Internal compartment 15 comprises therapeutic
3 composition containing hydromorphone 14, described in detail in drawing
4 Figure 2. The therapeutic composition of drawing Figure 2 is identified in
5 drawing Figure 3 as layer 20 or therapeutic hydromorphone layer 20. Layer
6 20 comprises the ingredients described in drawing Figure 2 and the details
7 previously disclosed are included in this description of drawing Figure 3.
8 Layer 20 in drawing Figure 3 initially is in contact with expandable layer 21.

9 Expandable layer 21 comprises 20 mg to 375 mg of an expandable
10 osmopolymer 22, represented by "V". The osmopolymer 22 in layer 21
11 possesses a higher molecular weight than osmopolymer 16 in the therapeutic
12 hydromorphone composition. The osmopolymer 22 comprises a member
13 selected from the group consisting of a polyalkylene oxide and a
14 carboxyalkylcellulose. The polyalkylene oxide possesses a 1,000,000 to
15 10,000,000 weight-average molecular weight. Representative of polyalkylene
16 oxide include a member selected from the group consisting of polymethylene
17 oxide, polyethylene oxide, polypropylene oxide, polyethylene oxide having a
18 1,000,000 molecular weight, polyethylene oxide comprising a 5,000,000
19 molecular weight, polyethylene oxide comprising a 7,000,000 molecular
20 weight, cross-linked polymethylene oxide possessing a 1,000,000 molecular
21 weight, and polypropylene oxide of 1,200,000 molecular weight. Typical
22 osmopolymer 22 carboxyalkylcellulose comprises a member selected from
23 the group consisting of alkali carboxyalkylcellulose, sodium
24 carboxymethylcellulose, potassium carboxymethylcellulose, sodium
25 carboxyethylcellulose, lithium carboxymethylcellulose, sodium
26 carboxyethylcellulose, carboxyalkylhydroxyalkylcellulose,
27 carboxymethylhydroxyethyl cellulose, carboxyethylhydroxyethylcellulose and
28 carboxymethylhydroxypropylcellulose. The osmopolymers used for the
29 expandable layer exhibit an osmotic pressure gradient across semipermeable
30 wall 12. The osmopolymers imbibe fluid into dosage form 10, thereby

09905526-071301

1 swelling and expanding as an osmotic hydrogel (also known as osmogel)
2 whereby, they push the hydromorphone from the osmotic dosage form. The
3 amount of osmopolymer 22 in expandable layer 21 is 20 to 375 mg.

4 Expandable layer 21 comprises 0 to 75 mg and presently 5 to 75 mg of
5 an osmotically effective compound 23, represented by circles. The
6 osmotically effective compounds are known also as osmagents and as
7 osmotically effective solutes. They imbibe an environmental fluid, for
8 example, from the gastrointestinal tract, into dosage form 10, for contributing
9 to the delivery kinetics of expandable layer 21. Representative of osmotically
10 active compounds comprise a member selected from the group consisting of
11 osmotic salts, and osmotic carbohydrates. Representative of specific
12 osmagents include sodium chloride, potassium chloride, magnesium sulfate,
13 lithium phosphate, lithium chloride, sodium phosphate, potassium sulfate,
14 sodium sulfate, potassium phosphate, glucose, fructose and maltose.

15 Expandable layer 21 comprises 1 to 75 mg of a hydroxypropylalkyl-
16 cellulose, represented by triangles. The hydroxypropylalkylcellulose
17 possesses a 9,000 to 450,000 number-average molecular weight. The
18 hydroxypropylalkylcellulose is represented by a member selected from the
19 group consisting of hydroxypropylmethylcellulose, hydroxypropylethyl-
20 cellulose, hydroxypropylisopropylcellulose, hydroxypropylbutylcellulose, and
21 hydroxypropylpentylcellulose. Expandable layer 21 optionally comprises a
22 hydroxyalkylcellulose, also represented by triangles. The hydroxyalkyl-
23 cellulose comprises a member selected from the group consisting of
24 hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and
25 hydroxybutylcellulose comprising a 7,500 to 150,000 viscosity-average
26 molecular weight. The amount of hydroxyalkylcellulose in the layer is 0.00
27 mg to 40 mg.

28 Expandable layer 21 comprises 0 to 5 mg of a nontoxic colorant or dye
29 25, identified by vertical wave lines. Colorant 25 includes Food and Drug
30 Administration Colorant (FD&C), such as FD&C No. 1 blue dye, FD&C No. 4

09905526.071301

1 red dye, red ferric oxide, yellow ferric oxide, titanium dioxide, carbon black,
2 and indigo. A lubricant 26, identified by half circles, is formulated into
3 expandable layer 21. Typical lubricants, comprise a member selected from
4 the group consisting of sodium stearate, potassium stearate, magnesium
5 stearate, stearic acid, calcium stearate, sodium oleate, calcium palmitate,
6 sodium laurate, sodium ricinoleate, and potassium linoleate. The concentrate
7 of lubricant is 0.01 to 10 mg.

8 An antioxidant 27, represented by slanted dashes, is present in
9 expandable formulation 21 to inhibit the oxidation of ingredients comprising
10 expandable formulation 21. Expandable formulation 21 comprises 0.00 to 5
11 mg of an antioxidant. Representative antioxidants comprise a member
12 selected from the group consisting of ascorbic acid, ascorbyl palmitate,
13 butylated hydroxyanisole, a mixture of 2 and 3 tertiary-butyl-4-hydroxyanisole,
14 butylated hydroxytoluene, sodium isoascorbate, dihydroguaric acid,
15 potassium sorbate, sodium bisulfate, sodium metabisulfate, sorbic acid,
16 potassium ascorbate, vitamin E, 4-chloro-2, 6-ditertiary butylphenol, alpha-
17 tocopherol, and propylgallate.

18 Dosage form 10, as seen in drawing Figure 4, depicts another
19 manufacture provided by the invention. Dosage form 10 comprises an
20 overcoat 28 on the outer surface of wall 12 of dosage form 10. The overcoat
21 28 is a therapeutic composition comprising 0.5 to 75 mg of hydromorphone
22 14 and 0.5 to 275 mg of a pharmaceutically acceptable carrier selected from
23 the group consisting of alkylcellulose, hydroxyalkylcellulose and
24 hydroxypropylalkylcellulose. The overcoat is represented by methylcellulose,
25 hydroxyethylcellulose, hydroxybutylcellulose, hydroxypropylcellulose,
26 hydroxypropylmethylcellulose, hydroxypropylethylcellulose and
27 hydroxypropylbutylcellulose. Overcoat 28 provides therapy immediately as
28 overcoat 28 dissolves or undergoes dissolution in the presence of
29 gastrointestinal fluid and concurrently therewith delivers hydromorphone 14
30 into the gastrointestinal tract for immediate hydromorphone therapy.

09905526-071304

Dosage form 10, manufactured as an osmotically controlled-release dosage form, comprises at least one passageway 13. The phrase "controlled-release" as used herein indicates that control is exercised over both the duration and the profile of the hydromorphone release pattern. The expression "passageway" as used for the purpose of this invention, includes aperture, orifice, bore, pore, porous element through which hydromorphone drug 14 can be pumped, diffuse or migrate through a fiber, capillary tube, porous overlay, porous insert, microporous member, and porous composition. The passageway 13 includes also a compound that erodes or is leached from wall 12 in the fluid environment of use to produce at least one passageway. Representative compounds for forming a passageway include erodible poly(glycolic) acid, or poly(lactic) acid in the wall; a gelatinous filament; a water-removable poly(vinyl alcohol); leachable compounds such as fluid-removable pore-forming polysaccharides, acids, salts or oxides. A passageway can be formed by leaching a compound from wall 12, such as sorbitol, sucrose, lactose, maltose, or fructose, to form a controlled-release dimensional pore-passageway. The passageway can have any shape, such as round, triangular, square and elliptical, for assisting in the controlled-metered release of hydromorphone 14 from the dosage form. The dosage form can be manufactured with one or more passageways in spaced-apart relation on one or more surfaces of the dosage form. A passageway and equipment for forming a passageway are disclosed in U.S. Patents Nos. 3,845,770 and 3,916,899 by Theeuwes and Higuchi; in U.S. Patent No. 4,063,064 by Saunders et al.; and in U.S. Patent No. 4,088,864 by Theeuwes et al. Passageways comprising controlled-release dimensions sized, shaped and adapted as a releasing-pore formed by aqueous leaching to provide a releasing-pore of a controlled-release rate are disclosed in U.S. Patent Nos. 4,200,098 and 4,285,987 by Ayer and Theeuwes.

09905526-071301

PROCESS FOR PROVIDING THE INVENTION

Wall 12 of dosage form 10 is manufactured in one process comprising an air suspension process. This process consists in suspending and tumbling a compressed drug core comprising a single-layered core or a bilayered core in a current of air and wall-forming composition until a wall is applied to the single-layered core or the bilayered core. The air suspension procedure is well suited for independently forming the wall. The air suspension procedure is described in U.S. Patent No. 2,799,241; J Amer Pharm Assoc, Vol. 48, pp. 451-454 (1959); and ibid.; Vol. 49, pp. 82-84 (1960). Dosage form 10 can be coated also with a wall-forming composition in an air suspension coater using a solvent, such as a methylene dichloride-methanol cosolvent comprising 80:20 wt:wt, or an ethanol-water cosolvent, or an acetone-water cosolvent consisting of 95:5 wt:wt using 2.5 to 4% solvents.

An air suspension coater using a methylene dichloride-methanol cosolvent, for example, 80:20 wt:wt, can be used for applying the wall. Other wall-forming techniques, such as a pan-coating system wherein wall-forming compositions are deposited by successive spraying of the drug-core composition to provide a wall that defines and surrounds a compartment, accompanied by tumbling in a rotating pan. Finally, the wall-coated cores are dried in an oven, forced or nonforced air oven, at 30-50°C for up to a week to free the dosage form of solvent. The walls formed by these techniques have a thickness of 1 to 30 mils (0.0254 to 0.762 mm).

Dosage form 10 of the invention is manufactured by other manufacturing techniques. For example, in one manufacture the drug and other core-forming ingredients comprising a single drug layer or bilayer core with drug facing the exit means 13 are blended and pressed into a solid layer or a solid bilayer. The drug and other ingredients can be dry-blended or blended with a solvent and mixed into a solid or semisolid formed by conventional methods such as ball-milling, calendaring, stirring, roll-milling, or churning, and can then be pressed into a preselected shape. The layer

09905526-071304

1 possesses dimensions that correspond to the internal dimensions of the area
2 the single layer occupies in the dosage form, or in a bilayer where it also
3 possesses dimensions corresponding to the first and second layer for forming
4 a contacting arrangement therewith. In a bilayered core, the push layer is
5 placed in contact with the drug layer. The push layer is manufactured using
6 techniques for providing the drug layer. The layering of the drug layer and the
7 push layer can be fabricated by conventional press-layering techniques.
8 Finally, a single layer or a two-layer compartment forming members are
9 surrounded and coated with an exterior wall. A passageway is provided, such
10 as by laser or mechanically drilled through the wall to contact the drug layer.
11 When the passageway is formed by a laser, the dosage form is optically
12 oriented automatically by the laser equipment for forming the passageway on
13 the preselected surface for forming the passageway.

14 In another manufacture, dosage form 10 is manufactured by a
15 granulation technique. Granulation is a process of size enlargement whereby
16 small particles are gathered into larger aggregates in which the original
17 particles can still be identified. Granulation can be divided into a dry method,
18 wherein no liquid is used for the aggregation, or into a wet method, wherein a
19 liquid is used for granule agglomeration of powder particles followed by a
20 drying process. Granulation is reported in Encyclopedia of Pharmaceutical
21 Technology, Vol. 7, pp. 121-160, (1993), published by Marcel Dekker, Inc. In
22 the wet granulation technique, for example, the drug and other ingredients
23 comprising the composition or drug-forming layer, or the drug-forming
24 expandable bilayer core are blended using a solvent, such as ethyl alcohol-
25 water 98:2 v:v (volume:volume) as the granulation fluid. Other granulating
26 fluid, such as denatured alcohol 100%, can be used for this purpose. The
27 ingredients forming the drug core or bilayers are individually passed through a
28 mesh screen, such as a U.S. Sieve Series screen, and then thoroughly
29 blended in a mixer. Other ingredients comprising the layer or layers are
30 dissolved in a portion of the granulation fluid, such as the cosolvent described

09905526-071301

1 above. Then, the latter prepared wet blend is added slowly to the drug blend
2 with continual mixing in the blender. The granulating fluid is added until a wet
3 blend is produced, which wet mass is then forced through a mesh screen
4 onto oven trays. The blend is dried for 18 to 24 hours at 30-50°C. The dry
5 granules are then sized with a mesh screen. Next, a lubricant is passed
6 through a screen and added to the dry screen granule blend. The granulation
7 is placed in a blender and blended for 1 to 15 minutes. A push layer is made
8 by the same wet granulation, which consists in suspending and tumbling the
9 two contacting layers in a current of air until the wall-forming composition
10 surrounds the layers. The air suspension procedure is described in U.S.
11 Patent No. 2,799,241; J Amer Pharm Assoc, Vol. 48, pp. 451-454 (1979); and
12 ibid., Vol. 49, pp. 82-84 (1960). Other standard manufacturing procedures
13 are described in Modern Plastics Encyclopedia, Vol. 46, pp. 62-70 (1969);
14 and Pharmaceutical Sciences, Remington, 14th Ed., pp. 1626-1678 (1970),
15 Mack Publishing Co., Easton, PA. Granulation techniques are described in
16 ibid., pp. 1655-1660 (1970).

17 Exemplary solvents suitable for manufacturing the wall, a single layer
18 and a bilayer include inert inorganic and organic solvents. The solvents
19 include members selected from the group consisting of aqueous solvents,
20 alcohols, ketones, esters, ethers, aliphatic hydrocarbons, halogenated
21 solvents, cycloaliphatics, aromatics, heterocyclic solvents, and mixtures
22 thereof. Typical solvents include acetone, diacetone, alcohol, methanol,
23 ethanol, isopropyl alcohol, butyl alcohol, methyl acetate, ethyl acetate,
24 isopropyl acetate, n-butyl acetate, methyl isobutyl ketone, methyl propyl
25 ketone, n-hexane, n-heptane, ethylene glycol monoethyl ether, ethylene
26 glycol monoethyl acetate, methylene dichloride, ethylene dichloride,
27 propylene dichloride, carbon tetrachloride, chloroform, nitroethane,
28 nitropropane, tetrachloroethane, ethyl ether, isopropyl ether, cyclohexane,
29 cyclooctane, benzene, toluene, naphtha, tetrahydrofuran, diglyme, aqueous
30 and nonaqueous mixtures thereof, such as acetone and water, acetone and

FOET 20 92550660

1 methanol, acetone and ethyl alcohol, methylene dichloride and methanol, and
2 ethylene dichloride and methanol.

4 DESCRIPTION OF EXAMPLES OF THE INVENTION

5 The following examples are illustrative of the present invention and
6 they should not be considered as limiting the scope of the invention in any
7 way, as these examples and other equivalents thereof will become apparent
8 to those versed in the art in light of the present disclosure, drawings and
9 accompanying claims.

11 Example 1

12 A novel therapeutic composition comprising hydromorphone, wherein
13 the hydromorphone is a member selected from the group consisting of
14 hydromorphone pharmaceutically acceptable base and hydromorphone
15 pharmaceutically acceptable salt, is prepared as follows: First, 175 g. of
16 hydromorphone hydrochloride, 647.5 g of poly(ethylene oxide) possessing a
17 200,000 molecular weight, and 43.75 g of poly(vinyl pyrrolidone) having an
18 average-molecular weight of 40,000 are added to planetary mixing bowl and
19 the ingredients dry mixed for ten minutes. Then, 331 g of denatured
20 anhydrous alcohol is slowly added to the blended ingredients, with continuous
21 blending for approximately ten minutes. Next, the freshly prepared wet
22 granulation is passed through a 20-mesh screen, allowed to dry at 25°C for
23 about 20 hours, and then passed through a 16-mesh screen. Next, the
24 granulation is transferred to the planetary mixer and lubricated with 8.75 g of
25 magnesium stearate to produce a therapeutic hydromorphone composition.
26 The composition is compressed into tablets comprising 35 mg of
27 hydromorphone hydrochloride. The tablets are compressed under 8.5 tons of
28 pressure to provide extended-release hydromorphone hydrochloride tablets.

Example 2

The therapeutic compositions manufactured by following the above example provide compositions comprising 1 to 500 mg of a member selected from the group consisting of hydromorphone, hydromorphone base, hydromorphone salt and hydromorphone derivative; at least one polymeric carrier for the hydromorphone selected from 20 to 375 mg of poly(alkylene oxide) comprising a 50,000 to 750,000 molecular weight represented by poly(methylene oxide), poly(ethylene oxide), poly(propylene oxide), poly(isopropylene oxide) and poly(butylene oxide), or a polymeric carrier for the hydromorphone consisting of 20 to 375 mg of carboxymethylcellulose having a 10,000 to 175,000 molecular weight represented by a member selected from the group consisting of alkali carboxymethylcellulose, sodium carboxymethylcellulose and potassium carboxymethylcellulose; 0.01 to 25 mg of poly(vinyl) polymer possessing a 5,000 to 350,000 molecular weight represented by poly(vinyl pyrrolidone), copolymer of poly(vinyl pyrrolidone and vinyl acetate), copolymer of poly(vinyl pyrrolidone and vinyl alcohol), copolymer of poly(vinyl pyrrolidone and vinyl chloride), copolymer of poly(vinyl pyrrolidone and vinyl fluoride), copolymer of poly(vinyl pyrrolidone and vinyl butyrate), copolymer of poly(vinyl pyrrolidone and vinyl laurate), and copolymer of poly(vinyl pyrrolidone with vinyl stearate); and 0 to 10 mg of a lubricant represented by a member selected from the group consisting of magnesium stearate, calcium stearate, potassium oleate, sodium stearate, stearic acid and sodium palmitate. The therapeutic composition may contain other ingredients, for example, colorants, compression aids and binders. The composition can be compressed at ¼ to 10-ton force to yield an orally administrable tablet comprising hydromorphone.

Example 3

The therapeutic composition provided by the invention can be dry compressed into an orally administrable dosage form. For example, a mixture

1 of dry-powder ingredients comprising a hydromorphone pharmaceutically
2 acceptable base or a hydromorphone pharmaceutically acceptable salt as
3 represented by: hydrochloride, hydrobromide, sulfate, bisulfate, acetate,
4 valerate, oxalate, oleate, laureate, borate, benzoate, lactate, phosphate,
5 tosylate, citrate, maleate, fumarate, succinate, tartrate and napsylate; a tablet
6 excipient represented by 0 to 200 mg of microcrystalline cellulose; 20 to 375
7 mg of sodium carboxymethylcellulose of 10,000 to 175,000 molecular weight;
8 0.01 to 25 mg of a binder agent represented by poly(vinyl pyrrolidone) of
9 5,000 to 350,000 molecular weight, a hydroxypropylmethylcellulose of 9,200
10 to 75,000 molecular weight, and gelatin; and 0 to 10 mg of a lubricant, such
11 as stearic acid, calcium stearate or magnesium stearate; are dried, sieved
12 and mixed with other optional ingredients, such as a surfactant and a
13 flavoring agent, then fed to a tablet press and compressed to yield dry-
14 compressed hydromorphone tablets for oral administration to a patient in
15 need of hydromorphone analgesic pain relief. In a manufacture provided by
16 the invention a therapeutic composition made by wet-granulation or dry-
17 granulation processes can be surrounded with a semipermeable, polymeric
18 wall. The semipermeable wall is pervious to fluid, impervious to
19 hydromorphone, and an exit means, such as a passageway through the
20 semipermeable wall, provides for the delivery of hydromorphone at a
21 controlled-sustained rate through the exit means over time.

Example 4

24 A dosage form, adapted, designed and shaped as an osmotic drug
25 delivery device is manufactured as follows: First, 175 g of hydromorphone
26 hydrochloride, 647.5 g of poly(ethylene oxide) possessing a 200,000 mole-
27 cular weight, and 43.75 g of poly(vinyl pyrrolidone) having a 40,000 molecular
28 weight are added to a mixer and mixed for ten minutes. Then,
29 331 g of denatured anhydrous alcohol is added to the blended materials,

0905526-071301

1 with continuous mixing for ten minutes. Then, the wet granulation is passed
2 through a 20-mesh screen, allowed to dry at room temperature for 20 hours,
3 and then passed through a 16-mesh screen. Next, the granulation is
4 transferred to the mixer, mixed, and lubricated with 8.75 g of magnesium
5 stearate.

6 Then, a displacement or push composition for pushing the therapeutic
7 hydromorphone composition from the dosage form is prepared as follows:
8 First, 3910 g of hydroxypropylmethylcellulose possessing a 11,200 molecular
9 weight is dissolved in 45,339 g of water. Then, 101 g of butylated
10 hydroxytoluene is dissolved in 650 g of denatured anhydrous alcohol. Next,
11 2.5 kg of the hydroxypropylmethylcellulose aqueous solution is added, with
12 continuous mixing, to the butylated hydroxytoluene alcohol solution. Then,
13 the binder solution preparation is completed by adding, with continuous
14 mixing, the remaining hydroxypropylmethylcellulose aqueous solution to the
15 butylated hydroxytoluene alcohol solution.

16 Next, 36,000 g of sodium chloride is sized using a mill equipped with a
17 21-mesh screen. Then, 1200 g of ferric oxide is passed through a 40-mesh
18 screen. Then, the screened materials, 76,400 g of pharmaceutically
19 acceptable poly(ethylene oxide) possessing a 7,500,000 molecular weight,
20 and 2500 g of hydroxypropylmethylcellulose having a 11,200 molecular
21 weight are added to the bowl of a fluid bed granulator. The bowl is attached
22 to the granulator and the granulation process is initiated for effecting
23 granulation. Next, the dry powders are air suspended and mixed for ten
24 minutes. Then, the binder solution is sprayed from three nozzles onto the
25 powder. The granulating is monitored during the process as follows: total
26 solution spray rate of 800 g/min; inlet temperature of 43°C; and an air flow of
27 4300 m³/hr. At the end of the solution spraying process, 45,033 g of the
28 coated, granulated particles are dried for 35 minutes at room temperature.
29 The granules are sized using a mill with a 8-mesh screen. The granulation is

09905526-071301

1 transferred to a tumbler, mixed, and lubricated with 281.7 g of magnesium
2 stearate.

3 Next, the drug composition comprising the hydromorphone
4 hydrochloride and the push composition is compressed into bilayer tablets on
5 a tablet press. First, 176 mg of the hydromorphone hydrochloride
6 composition is added to the die cavity and precompressed. Then, 135 mg of
7 the push composition is added, and the layers are pressed under a pressure
8 head of 3-metric tons into a 11/32 in. (0.873 cm) diameter, contacting layer
9 arrangement.

10 The bilayered arrangements are coated with a semipermeable wall.
11 The wall-forming composition comprises 100% cellulose acetate having a
12 39.8% acetyl content. The wall-forming composition is dissolved in
13 acetone:water (95:5 wt:wt) cosolvent to make a 4%-solid solution. The wall-
14 forming composition is sprayed onto and around the bilayers in a 24-inch
15 coater.

16 Next, one 20 mil (0.508 mm) exit passageway is drilled through the
17 semipermeable wall to connect the drug hydromorphone layer with the
18 exterior of the dosage form. The residual solvent is removed by drying for
19 72 hours at 45°C and 45% humidity. Next, the osmotic dosage systems are
20 dried for four hours at 45°C to remove excess moisture. The dosage form
21 produced by this manufacture comprises 35.20 mg of hydromorphone
22 hydrochloride, 130.24 mg of poly(ethylene oxide) of 200,000 molecular
23 weight, 8.80 mg of poly(vinyl pyrrolidone) of 40,000 molecular weight, and
24 1.76 mg of magnesium stearate. The push composition comprises 85.96 mg
25 of poly(ethylene oxide) of 7,500,000 molecular weight, 40.50 mg of sodium
26 chloride, 6.75 mg of hydroxypropylmethylcellulose, 1.35 mg of red ferric
27 oxide, 0.34 mg of magnesium stearate, and 0.10 mg of butylated
28 hydroxytoluene. The semipermeable wall comprises 38.6 mg of cellulose
29 acetate comprising a 39.8% acetyl content. The dosage form comprises one
30 20 mil (0.508 mm) passageway, and the dosage form has a hydromorphone

09905526-071301

1 hydrochloride mean release rate of 1.6 mg/hr over an extended period of 28
2 hours.

3

4

Example 5

5

6

7

8

9

10

Example 6

11

12

13

14

15

16

17

18

19

20

21

Example 7

22

23

24

25

26

27

28

29

30

The dosage form prepared by the above examples can be manufactured with a semipermeable wall composition comprising 65 to 100 wt% of a cellulose polymer comprising a member selected from the group consisting of: cellulose ester, cellulose diester, cellulose triester, cellulose ether, cellulose ester-ether, cellulose acylate, cellulose diacylate, cellulose triacetate, cellulose acetate butyrate, and the like. The wall can also comprise from 0 to 40 wt% of a cellulose ether selected from the group consisting of: hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose and hydroxypropyl-

09905526-071301

1 pencylcellulose. The wall can further comprise 0 to 20 wt% of polyethylene
2 glycol. The total amount of all components comprising the wall is equal to
3 100 wt%. Semipermeable polymers are disclosed in U.S. Patent Nos.
4 3,845,000, 3,916,899, 4,008,719, 4,036,228 and 4,111,201. These patents
5 are assigned to the ALZA Corporation of Palo Alto, CA, the assignee of this
6 patent application.

7 In another manufacture, the wall can be prepared according to the
8 above examples comprising the selectively permeable cellulose ether: ethyl
9 cellulose. The ethyl cellulose comprises an ethoxy group with a degree of
10 substitution (DS) of about 1.4 to 3, equivalent to 40 to 50% ethoxy content,
11 and a viscosity range of 7 to 100 centipoise or higher. A representative wall
12 comprises 45 to 80 wt% ethylcellulose, from 5 to 30 wt% hydroxypropyl-
13 cellulose, and from 5 to 30 wt% polyethylene glycol, with the total amount of
14 all components comprising the wall equal to 100 wt%. In another
15 manufacture, the wall comprises 45 to 80 wt % ethylcellulose, 5 to 30 wt%
16 hydroxypropylcellulose, and 2 to 20 wt% poly(vinyl pyrrolidone). The total
17 amount of all components comprising the wall is equal to 100 wt%. The
18 ethylcellulose polymer is known in U.S. Patent No. 4,519,801, assigned to the
19 ALZA Corporation of Palo Alto, CA.

20 21 **Example 8**

22 The dosage form provided by the invention comprises a hydro-
23 morphine drug composition consisting of 1 to 500 mg of hydromorphone,
24 hydromorphone base, hydromorphone salt or hydromorphone derivative; at
25 least one of 20 to 375 mg of poly(alkylene oxide) of 50,000 to 750,000
26 molecular weight, or 25 to 375 mg of a carboxymethylcellulose of 10,000 to
27 175,000 molecular weight; at least one of 0.01 to 25 mg of a poly(vinyl
28 pyrrolidone) of 5,000 to 350,000 molecular weight, or 0 to 50 mg of a
29 hydroxypropylcellulose or hydroxypropylalkylcellulose of 7,500 to 75,000

1 molecular weight; and 0.01 to 10 mg of a lubricant, such as magnesium
2 stearate.

3 The dosage form provided by the invention comprises a push
4 composition consisting of at least one of 20 to 375 mg of a poly(alkylene
5 oxide) of 1,000,000 to 10,000,000 molecular weight, or 20 to 425 mg of a
6 carboxymethylcellulose, such as sodium carboxymethylcellulose, and a
7 potassium carboxymethylcellulose of 200,000 to 7,500,000, molecular weight;
8 0 to 75 mg of an osmagent, also known as osmotically effective solute,
9 represented by magnesium sulfate, sodium chloride, lithium chloride,
10 potassium sulfate, sodium sulfate, lithium sulfate, potassium acid phosphate,
11 mannitol, urea, inositol, magnesium succinate, tartaric acid, carbohydrates
12 such as raffinose, sucrose, glucose, lactose, fructose, sodium chloride and
13 fructose, potassium chloride and dextrose; 1 to 75 mg of a hydroxyalkyl-
14 cellulose selected from the group consisting of hydroethylcellulose,
15 hydroxypropylcellulose, hydroxyisopropylcellulose, hydroxybutylcellulose,
16 hydroxypropylmethylcellulose, hydroxypropylethylcellulose, and
17 hydroxypropylbutylcellulose, which hydroxyalkylcellulose comprises a 9,000
18 to 450,000 molecular weight; 0 to 10 mg of an antioxidant represented by
19 d-alpha tocopherol acetate, dl-alpha tocopherol, ascorbyl palmitate, butylated
20 hydroxyanisole, butylated hydroxytoluene and propyl gallate; 0 to 10 mg of a
21 lubricant represented by magnesium stearate, calcium stearate; corn starch,
22 potato starch, bentonite, citrus pulp, and stearic acid; and 0 to 10 mg of a
23 colorant.

24 Examples 9 - 12

25 Dosage forms are provided by following the above procedures
26 comprising the following: (A) A dosage form with a drug layer comprising 8
27 mg of hydromorphone hydrochloride, 67.8 mg of poly(ethylene oxide)
28 possessing a 200,000 molecular weight, 4 mg of poly(vinyl pyrrolidone) of
29 42,000 molecular weight, and 0.8 mg of magnesium stearate; a hydrogel,
30

1 expandable layer comprising 37.80 mg of poly(ethylene oxide) possessing a
2 2,000,000 molecular weight, 30 mg of osmagent sodium chloride, 3 mg of
3 hydroxypropylmethylcellulose of 9,200 molecular weight, 0.6 mg of red ferric
4 oxide, and 0.15 mg of lubricant magnesium stearate; a semipermeable wall
5 comprising 27.2 mg of cellulose acetate of 39.8% acetyl content, and 0.275
6 mg of polyethylene glycol of 3,350 molecular weight; a mean release rate of
7 0.427 mg/hr for 17.3 hours; and a 25 mil (0.635 mm) passageway; (B) a
8 dosage form with a hydromorphone drug layer comprising 32 mg of
9 hydromorphone hydrochloride, 119.6 mg of poly(ethylene oxide) possessing a
10 200,000 molecular weight, 8 mg of poly(vinyl pyrrolidone) of 42,000 molecular
11 weight, and 0.4 mg of magnesium stearate; an expandable layer comprising
12 76.49 mg of hydrogel poly(ethylene oxide) of 2,000,000 molecular weight, 36
13 mg of osmagent sodium chloride, 6 mg of hydroxypropylmethyl-cellulose of
14 9,200 molecular weight, 1.2 mg of red ferric oxide, and 0.012 mg of butylated
15 hydroxytoluene antioxidant; a semipermeable wall comprising 29.6 mg of
16 cellulose acetate comprising an acetyl content of 39.8%, and 0.29 mg of
17 polyethylene glycol of 3,350 molecular weight; a hydromorphone controlled-
18 release rate of 1.811 mg/hr for 16.1 hours; and a 25 mil (0.635 mm)
19 passageway; (C) a dosage form comprising a hydromorphone drug layer
20 comprising 64.0 mg of hydromorphone hydrochloride, 138.6 mg of
21 poly(ethylene oxide) of 200,000 molecular weight, and 0.53 mg of lubricant
22 magnesium stearate; a delivery layer comprising 104.533 mg of poly(ethylene
23 oxide) of 2,000,000 molecular weight, 49.2 mg of osmagent sodium chloride,
24 8.2 mg of hydroxypropylmethylcellulose of 9,200 molecular weight, 1.64 mg of
25 red ferric oxide colorant, 0.41 mg of magnesium stearate lubricant, and
26 0.0164 mg of antioxidant butylated hydroxytoluene; a semipermeable wall
27 comprising 38.61 mg of cellulose acetate comprising a 39.8% acetyl content,
28 and 0.39 mg of polyethylene glycol of 3,350 molecular weight; a controlled
29 rate of release of 3.77 mg/hr over an extended period of 15.3 hours; and a 25
30 mil (0.635 mm) passageway for delivering the hydromorphone from the

0905526-071301

1 dosage form; and (D) a dosage form comprising 16 mg of hydromorphone
2 hydrochloride, 135.6 mg of poly(ethylene oxide) of 200,000 molecular weight,
3 8 mg of poly(vinyl pyrrolidone) of 42,000 molecular weight, and 0.4 mg of
4 lubricant magnesium stearate; a hydrogel delivery layer comprising 76.49 mg
5 of poly(ethylene oxide) of 2,000,000 molecular weight; 36 mg of osmagent
6 sodium chloride, 6 mg of hydroxypropylmethylcellulose, 1.2 mg of black ferric
7 oxide colorant, 0.3 mg of magnesium stearate lubricant, 0.12 mg of
8 antioxidant butylated hydroxytoluene; a semipermeable wall comprising 27.52
9 mg of cellulose acetate of 39.8% acetyl content, and 0.27 mg of polyethylene
10 glycol of 3,350 molecular weight; a controlled release rate of 0.957 mg/hr for
11 15.0 hours; and a 25 mil (0.635 mm) passageway.

12 13 **Example 13**

14 A dosage form is provided by following the above teachings, wherein
15 the dosage form delivers 0.4 to 3.7 mg/hr at a controlled rate, over an
16 extended time up to 24 hours, to provide hydromorphone to a patient in need
17 of same.

18 19 **Example 14**

20 The dosage form prepared according to Example 13, wherein the
21 dosage form comprises 10 to 100 mg of hydromorphone.

22 23 **Example 15**

24 A dosage form is provided by following the above disclosure, wherein
25 the dosage form comprises 2 to 75 mg of hydromorphone that is administered
26 over 24 hours to produce from greater than zero ng to 10 ng/ml of plasma,
27 generally from 0.01 ng to 10 ng/ml, for producing a plasma hydromorphone
28 concentration.

29
30

09905526-071301

Example 16

A dosage form adapted, designed and shaped as an osmotic drug delivery device is manufactured as follows: first, sublots of drug granulation were manufactured as follows: first, 2000 g of hydromorphone hydrochloride, 16,950 g of a pharmaceutically acceptable poly(ethylene oxide) comprising a 200,000 average molecular weight, 900 g of poly(vinyl-pyrrolidone) of 40,000 average molecular weight, are added to the bowl of a granulator, and the ingredients granulated to yield the granulation. Next, the dry granulated powders were all suspended and mixed thoroughly for three minutes. Then, a solution was prepared by dissolving 120 g of poly(vinylpyrrolidone) of 40,000 average molecular weight in 5,800 g of anhydrous ethyl alcohol and the solution sprayed onto the powder with mixing in a granulator bowl. The granulation is mixed for twenty minutes with constant addition of the solution. Then, the granulation is dried under vacuum to a moisture content of below 1.5%. The granulating conditions were as follows: a solution spray rate of 200 g/min; bowl temperature 25°C; vacuum between 40 and 80 millibar. The granules were sized in a fluid air mill with a 7 mesh screen (2.81 mm). The screen are U.S. Series, in Perry's Chemical Engineers' Handbook, Sixth Edition, pp 21-15, Table 21-6, (1984).

Next, the granulation was transferred to a tumbler and lubricated with mixing with 142 of magnesium stearate.

Next, a push composition was prepared as follows: first, a binder solution is prepared by dissolving 4000 g of hydroxypropylmethylcellulose of 11,200 average molecular weight in 46,000 g of water. Then, 36,000 g of sodium chloride osmagent was sized in a mill equipped with a 21 mesh screen. Then, 1200 g of ferric oxide was passed through a 40 mesh screen. Then, all the screened materials, and 76,400 g of pharmaceutically acceptable poly(ethylene oxide) comprising a 2,000,000 molecular weight. 2516 g of hydroxypropylmethylcellulose comprising an 11,200 average molecular weight were added to a fluid bed granulator bowl, and the

1 ingredients granulated to effect the process. The dry powders were an
2 suspended next, and mixed for 10 minutes. Then, the binder solution was
3 sprayed onto the powders at a rate of 700 g/min, at a temperature of 25°C,
4 and at an air flow between 500 and 4000 m³/hr.

5 Next, at the end of the solution spraying, 43,550 g of the granulated
6 granules were dried for 20 minutes. Then, the granules were sized in a mill
7 equipped with a 7 mesh screen. Then, the granulation was transferred to a
8 tumbler and mixed with 88.2 g of butylated hydroxytoluene and then mixed
9 with 294 g of magnesium stearate.

10 Next, the hydromorphone hydrochloride drug composition and the
11 push composition were compressed into bilayered tablets on a tablet press.
12 First, 80 mg of hydromorphone hydrochloride composition was added to a die
13 cavity and pre-compressed. Then, 60 g of the push composition was added
14 and the layers pressed under a pressure of 1200 pounds into a 9/32 inch
15 (0.71 cm) round-contacting layered arrangement.

16 Next, the bilayered arrangements were coated with a semipermeable
17 wall. The wall-forming composition comprises 99% cellulose acetate having a
18 39.8% acetyl content, and 1% polyethylene glycol having a 3350 molecular
19 weight. The wall-forming composition was dissolved in an acetone: water
20 (96:4 wt:wt) cosolvent to make a 4% solids solution. The wall-forming
21 composition was sprayed onto and around the bilayers in a coater. Next, one
22 25 mil (0.635 mm) exit passageway was drilled through the semipermeable
23 wall to connect the drug layer with the exterior of the dosage form. The
24 residual solvent was removed by drying for 96 hours at 45°C and 45%
25 humidity. The dosage forms were dried at 4 hours at 45°C to remove the
26 moisture.

27 The dosage form produced by this manufacture provides 10%
28 hydromorphone hydrochloride, 84.75% poly(ethylene oxide) possessing a
29 200,000 molecular weight, 5% poly(vinylpyrrolidone) possessing a 40,000
30 molecular weight and 0.25% magnesium stearate in the drug composition.

09905526-071301

1 The push composition comprises 63.675% poly(ethylene oxide) comprising a
2 2,000,000 molecular weight, 30% sodium chloride, 5% hydroxypropylmethyl-
3 cellulose comprising a 11,200 molecular weight, 1% ferric oxide, 0.075%
4 butylated hydroxytoluene and 0.25% magnesium stearate. The
5 semipermeable wall comprises 99 wt% cellulose acetate comprising a 39.8%
6 acetyl content, and 1% polyethylene glycol comprising a 3350 molecular
7 weight. The dosage form comprises one passageway, 2.5 mils (0.635 mm),
8 and the dosage form had a hydromorphone hydrochloride mean release rate
9 of 0.5 mg/hr.

EXAMPLES 17 to 20

12 The procedure set forth in Example 16 was repeated to manufacture
13 dosage forms as follows: (17) a dosage form comprising a drug layer of 80
14 mg comprising 8 mg of drug expressed as 10.5% hydromorphone
15 hydrochloride, 84.23% polyethylene oxide of 200,000 molecular weight, 5%
16 poly(vinylpyrrolidone of 40,000 molecular weight and 0.25 mg of magnesium
17 stearate; (18) a dosage form comprising a drug layer of 160 mg comprising
18 16 mg of hydromorphone hydrochloride, expressed in percent as 10%
19 hydromorphone hydrochloride, 84.75% poly(ethylene oxide) of 200,000
20 molecular weight, and 5% poly(vinylpyrrolidone of 40,000 molecular weight,
21 and 0.25% magnesium stearate; (19) a dosage form comprising a 160 mg
22 drug layer comprising 32 mg of hydromorphone hydrochloride expressed as
23 20% hydromorphone hydrochloride, 74.75% poly(ethylene oxide) of 200,000
24 molecular weight, 5% poly(vinylpyrrolidone) of 40,000 molecular weight, and
25 0.25 mg of magnesium stearate; and (20) a dosage form comprising a drug
26 composition of 214 mg comprising 64 mg of hydromorphone with the total
27 drug composition comprising 30% hydromorphone, 64.75% poly(ethylene
28 oxide) of 200,000 molecular weight, 5% poly(vinylpyrrolidone) of 40,000
29 molecular weight, and 0.25% magnesium stearate.

1 The push layer for the dosage forms of Examples 17, 18, 19, and 20
2 weighted 60, 120, 120 and 164 mg respectively. The push layers of
3 Examples 17, 18, 19 and 20 comprise 64.3% poly(ethylene oxide of
4 2,000,000 molecular weight, 30% sodium chloride, 5% hydroxypropyl-
5 methylcellulose of 11,200 molecular weight, 0.075% butylated
6 hydroxytoluene, 1% ferric oxide, and 0.25% magnesium stearate.

7 The semipermeable wall for the dosage forms of Examples 17, 18, 19
8 and 20 comprises 99% cellulose acetate of 39.8% acetyl content and 1%
9 polyethylene glycol of 3350 molecular weight. The dosage form comprise a
10 25 mil push composition as expressed in weight %. The dosage form
11 optionally comprise a color overcoat, white, yellow, blue or red.

12 DISCLOSURE FOR USING THE INVENTION

13
14 The invention also concerns a method for administering 1 to 500 mg of
15 hydromorphone to a patient in need of pain relief. The method, in one
16 administration, comprises admitting orally into the patient 1 to 500 mg of a
17 hydromorphone selected from the group consisting of hydromorphone base
18 or hydromorphone salt that is administered from a therapeutic composition, or
19 from a dosage form in an extended-release profile for a 16 mg, a 32 mg or 64
20 mg total dose of 0 to 20% in 0 to 4 hrs, 20 to 50% in 0 to 8 hrs, 55 to 85% in 0
21 to 14 hrs, and 80 to 100% in 0 to 24 hrs and for an 8 mg dosage form, no
22 more than 20 to 50% in 0 to 8 hrs, no more than 55 to 85% in 0 to 14 hrs, and
23 no less than 75 to 100% in 0 to 24 hrs.

24 The invention also concerns a method for administering 1 to 500 mg of
25 hydromorphone to a patient. The method comprises admitting orally 1 to 500
26 mg of hydromorphone to the patient, which is administered from a dosage
27 form comprising a semipermeable wall permeable to aqueous-biological fluid
28 and impervious to the passage of hydromorphone. The semipermeable wall
29 surrounds an internal space or compartment comprising a hydromorphone
30 drug composition and a push composition. The hydromorphone drug

09905526-071301

1 composition comprises 1 to 500 mg of hydromorphone, 20 to 375 mg of
2 poly(alkylene oxide) having a 50,000 to 750,000 molecular weight, 0.01 to 25
3 mg of poly(vinylpyrrolidone) having a 5,000 to 350,000 molecular weight, and
4 0 to 10 mg of a lubricant. The push composition comprises 20 to 375 mg of a
5 hydrogel polymer, such as a poly(alkylene oxide) of 1,000,000 to 10,000,000
6 molecular weight, 0 to 75 mg of an osmagent, 0 to 75 mg of hydroxyalkyl-
7 cellulose, 0.01 to 5.5 mg of a colorant, 0.01 to 10 mg of a lubricant, and 0 to
8 10 mg of an antioxidant; and exit means in the semipermeable wall for
9 delivering the hydromorphone from the dosage form by imbibing fluid through
10 the semipermeable wall into the dosage form, causing the hydromorphone
11 composition to become dispensable and causing the push composition to
12 expand and push the hydromorphone composition through the exit, whereby,
13 through the combined operations of the dosage form, the hydromorphone is
14 delivered at a therapeutically effective dose at a controlled rate over a
15 sustained period of time.

16 A clinical pharmacokinetic study was performed on healthy subjects to
17 ascertain the therapeutic benefits obtained by administering hydromorphone
18 from a controlled, extended-release dosage form provided by this invention,
19 compared to the therapeutic benefits obtained by administering
20 hydromorphone from an immediate-release dosage form. The study
21 evaluated both the single- and multiple-dose pharmacokinetics of
22 hydromorphone and its metabolite following oral administration of
23 hydromorphone. The dosing form of this invention was compared to an
24 immediate-release dosage form, dosing for four days.

25 The profile of the clinical study compared randomized, cross-over
26 doses using 18 healthy volunteers consisting of both male and female
27 patients. The controlled-extended release dosage form provided by the
28 invention was used to administer a 16-mg dose of hydromorphone orally at
29 8:00 AM for four days. The immediate-release dosage form was used to
30 administer 4 mg of hydromorphone orally every six hours at 8:00 AM, 2:00

FOI 2012-071301-92550660

1 PM, 8:00 PM, and 2:00 AM daily for four days. There was a washout period
2 of at least three days between the two treatments.

3 The administration of hydromorphone by the osmotic dosage form
4 provided by the invention was followed by the collection of venous blood
5 samples for pharmacokinetic profile determinations on day one and for 48
6 hours after the day-four dosing period. The administration of hydromorphone
7 by an immediate-release dosage form was followed by the collection of
8 venous blood samples for pharmacokinetic profile determinations for 48 hours
9 after the day-four dosing period. The immediate-release dosing form used in
10 the clinical studies comprised a solid tablet consisting of 4 mg of
11 hydromorphone, yellow dye, lactose and magnesium stearate, available by
12 prescription as Dilaudid® hydromorphone. The Physician's Desk Reference,
13 50th Ed., pp. 1335-1337 (1996).

14 The clinical samples were analyzed for hydromorphone parameters,
15 including area under the curve, maximum concentration, minimum
16 concentration and concentration average for the two distinctly different
17 hydromorphone treatments. The results of the clinical studies are presented
18 in the accompanying figures.

19 Figure 5 depicts the mean plasma hydromorphone concentration
20 profiles for hydromorphone treatment on days four and five. The osmotically
21 controlled extended-release dosage form results are illustrated by the solid
22 line with black circles. This dosage form was administered once-a-day, and it
23 comprised 16 mg of hydromorphone. The dashed line with clear squares in
24 Figure 5 depicts plasma profile for the immediate-release dosage form
25 administered four-times-a-day, which comprised 4 mg per immediate-release
26 dosage form.

27 Figure 6 depicts the mean plasma hydromorphone 3-glucuronide
28 concentration following hydromorphone treatment on days four and five. In
29 Figure 6, the solid line with black circles denotes the plasma profile for the
30 invention's osmotic dosage form administered once-a-day, which comprised

FOET20-92550660

1 16 mg of hydromorphone. The dashed lines with clear squares denote the
2 plasma profile for the immediate-release tablet orally administered four-times-
3 a-day, which comprised 4 mg for each administration.

4 Figure 7 depicts the mean plasma hydromorphone concentration
5 profiles for hydromorphone treatment on day four, determined at mealtime.
6 The solid line with black circles in this figure illustrates the clinical picture
7 effected by oral administration once-a-day of a 16 mg controlled-extended
8 release dosage form. The solid line with clear squares, in this figure,
9 illustrates the clinical picture effected by oral administration four-times-a-day
10 of a 4 mg immediate-release dosage form. The mean steady state
11 hydromorphone data for 18 subjects is for the immediate-release form
12 administered four-times-a-day, with 4 mg each time, a plasma concentration
13 maximum of 3.4 ng/ml with 10.1 hours to reach the maximum concentration,
14 a plasma concentration minimum of 0.9 ng/ml with 6.4 hours to reach the
15 concentration minimum, and an area under the curve of 41.2 ng-hr/ml. The
16 mean steady state hydromorphone data for 18 subjects is for the osmotic
17 dosage form administered once-a-day with a dose of 16 mg, a plasma
18 concentration maximum of 2.6 ng/ml with 14.7 hours to reach the maximum
19 concentration, a plasma concentration minimum of 1.2 ng/ml with 13.1 hours
20 to reach the minimum concentration, and an area under the curve of 44.8 ng-
21 hr/ml.

22 The invention provides methods for administering hydromorphone to a
23 patient, and methods for producing a plasma concentration of
24 hydromorphone. The method of the invention provides for admitting orally to
25 a patient a dosage form that administers at a controlled rate, over a
26 continuous time up to 24 hours, hydromorphone for its intended therapy. The
27 method also comprises administering orally to a patient a therapeutic dose of
28 hydromorphone from a single dosage form that administers the
29 hydromorphone over 24 hours. The method of the invention further
30 comprises administering hydromorphone for producing a first hydromorphone

09905526.071301

1 concentration in the plasma, a second, elevated hydromorphone
2 concentration in the plasma, and a third, continuous hydromorphone
3 concentration in the plasma.

4 The method of the invention also comprises administering
5 hydromorphone for producing a first plasma hydromorphone concentration in
6 from 0 to 8 hours, a second, elevated plasma hydromorphone concentration
7 in 8 to 12 hours, and a third, continuous plasma hydromorphone
8 concentration over 12 to 24 hours. The method provides pain relief in a
9 patient in need of pain relief. The method further provides a plasma
10 concentration of hydromorphone in a patient in need of hydromorphone
11 comprising orally administering to the patient a dosage form that provides a
12 controlled rate of extended administration of from 1 to 65 mg of
13 hydromorphone over a period of time up to 24 hours for producing from
14 greater than zero ng, including 0.01 ng, to 10 ng/ml of plasma of
15 hydromorphone for producing a plasma concentration of hemoglobin in a
16 human patient.

17 Further data that support the unexpected results provided by the
18 invention are seen in the accompanying figures, wherein Figure 8 depicts the
19 area under a curve for a dosage form comprising 8 mg of hydromorphone,
20 Figure 9 depicts the cumulative dose released from 8 mg dosage form over
21 25 hrs, Figure 10 depicts the cumulative dose release from a 16 mg dosage
22 form over 25 hrs, Figure 11 illustrates the cumulative dose release from a 32
23 mg dosage form over 25 hrs, and Figure 12 illustrates the cumulative dose
24 release from a 64 mg dosage form over 25 hrs.

25 In as much as the foregoing specification comprises disclosed
26 embodiments, it is understood what variations and modifications may be
27 made herein, in accordance with the principles disclosed, without departing
28 from the invention.

29

09905526.071301